Nixon Gwilt Law
DECEMBER 6, 2021
For the first time, the Drug Enforcement Agency (“DEA”) is becoming directly involved in the telepharmacy space, an industry that the DEA has not previously regulated aside from the loose application of its existing regulations governing online pharmacies. Want to read more about telepharmacy on our blog?
Contrarian Sales Techniques
DECEMBER 15, 2022
million for the prescriptions that Chun wrote for Subsys. The FBI's Tampa Division Special Agent David Walker said that the actions of the corrupt medical professional caused financial pain to the patients. He noted that the government's efforts to combat fraud and corruption are vital to the healthcare system's success.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
MAY 11, 2023
Mainland China has streamlined regulatory protocols for testing and approving prescription drugs in recent years, making dozens of urgently needed treatments, from domestic and international manufacturers alike, available to patients in the process. In parallel, the CDE also established a special channel to facilitate these approvals.
Clarify Health
NOVEMBER 21, 2022
Data governance and HIPAA rules around this are very clear—you can’t identify the individual. The characteristics of interest (e.g., age, geography, income, race) can be used as a filter, allowing companies to “cohort in their own way,” he says. Switzerland Platform’ .
Salesforce
MARCH 2, 2022
The problems afflicting the health industry are especially prevalent in government systems, which are slowed by political gridlock, budget constraints, and inertia. Case study: How Ireland’s government healthcare quickly prepared for COVID-19. government healthcare system. What’s the future of government healthcare systems?
European Pharmaceutical Review
NOVEMBER 15, 2022
As ISPE GAMP 5 Second Edition notes in the preface “Operating in a highly regulated industry may lead practitioners to apply prescriptive and rigid compliance-based approaches that are not commensurate with and not effective in managing any actual risk to the product and the patient.”
Eversana Intouch
FEBRUARY 23, 2023
Talent shortages continue, particularly in executive and specialized R&D roles, while simultaneously layoffs , especially in biotech, are on the rise. Shifts in government healthcare policy and funding. Biopharma valuations are down, especially for public and earlier-stage companies. Practice ownership financial challenges.
Expert insights. Personalized for you.
52 
Let's personalize your content